Categories Health Care, Research Summary
Trxade Health Inc. (NASDAQ: MEDS) Q4 2021 Research Summary
Trxade has authorized the resumption of its stock repurchase program with a modification that allows the buyback of up to a maximum of 100,000 shares
Trxade Health Inc. (NASDAQ: MEDS) is a healthcare service technology platform that mainly serves the secondary pharmaceutical supply chain, offering a web-based marketplace for integrated pharmaceutical and medical services. It connects pharmacies and consumers digitally by consolidating the pharma supply chain and health services verticals, with a focus on price transparency.
Headquartered in Florida, Trxade is on a mission to digitalize the retail pharmacy experience by optimizing drug procurement, prescription process, and patient engagement. The technology-enabled online marketplace serves more than 12,950 registered members in the U.S. and helps patients avail medicines and other health services at affordable prices. Bonum Health, the telehealth arm of Trxade that provides patient-centric services, has played an important role in facilitating remote healthcare delivery during the COVID-19 pandemic.
Read management/analysts’ comments on Trxade’s Q3 2021 earnings
The portfolio is designed to make specialty healthcare services — which were inaccessible to many people until recently — available to all sections of society. The company’s key products and services are:
- Bonum Health (Telehealth/Telemedicine App)
- Community Specialty Rx (Pharmacy)
- DelivMeds (Rx Delivery App)
- Integra Pharma Solutions (Virtual Wholesaler)
- MedCheks (Health Passport App)
- Trxade Marketplace (Rx Marketplace)
- Trxade Medical (Rx Marketplace)
- Trxade HSO (Health Services Org)
- TRx Savings Card (Prescription Discount Card)
The North American e-pharmacy market is estimated to grow at a compounded annual rate of 14.8% through 2025, due to the growing prevalence of chronic diseases, the launch of generic drugs, and the sharp increase in clinical trials. Trxade is a leading player in the segment, serving nearly half of all the independent pharmacies in the country. The company leverages its technological prowess and disruptive business model to grow in a market that has become increasingly competitive. By collaborating with global distribution channels, it looks to scale internationally.
Trxade’s main competitors include Rite Aid Corporation (NYSE: RAD), Walgreens Boots Alliance (NASDAQ: WBA), and UnitedHealth Group (NYSE: UNH). Interestingly, the company competes with both large players like Amazon.com (NASDAQ: AMZN) and relatively smaller firms like Script Health and Petmed Express Inc. (NASDAQ: PETS).
Recently, the board of directors authorized the resumption of the company’s stalled stock repurchase program, with a modification that allows buyback of up to a maximum of 100,000 shares. However, there is no time frame for the repurchase program.
In November, the company launched what it calls Discount Card, which allows independent pharmacies to continue offering discounts while protecting margins. The program is made possible through a tie-up with pharmacy benefits manager Paramount Rx. Earlier, Bonum Health had launched pre-paid digital telemedicine passes that would allow uninsured consumers to avail healthcare services.
The company generated profit in five of the past 12 quarters and maintained healthy margins. With zero debt, the balance sheet is quite strong. It posted total revenues of $2.6 million for the three months ended September 2021, which represents a 59% decline from the year-ago period when the top-line was bolstered by one-time gains from a spike in the demand for personal protective equipment. While the Trxade and Integra Pharma segments witnessed double-digit declines, Community Specialty Pharmacy sales were almost flat. Consequently, net loss widened to $1.3 million or $0.16 per share from $0.1 million or $0.02 per share in the third quarter of 2020. Around 250 new members were added to the network during the quarter.
In 2022, Trxade executives will focus on forging new partnerships to further expand the core business, adding new revenue streams by venturing into new areas, and better leveraging the Bonum Health business. Also, the management expects the company’s GPO programs to start contributing to revenues starting the second/third quarter of 2022. Meanwhile, the supply chain disruption caused by the pandemic remains a major concern as far as providing timely care to patients is concerned.
Pfizer stock research summary | Q3 2021
One of the main issues facing the prescription drug market is high costs, which make many drugs unaffordable to a large number of people. Lack of coordination among various segments of the healthcare delivery system and sluggish adoption of technology remains a hassle for efficient healthcare delivery. Also, new players face competition from cash-rich retailers like Walmart Inc. (NYSE: WMT) that enjoy an edge due to their financial strength. As far as pharmacy technology firms are concerned, monopolistic pharmacy benefit managers and retail chains also pose a challenge.
The performance of Trxade’s stock was lackluster in 2021 when its value nearly halved amid volatility. The stock is yet to emerge from the single-digit territory. However, MEDS entered the new year on a bright note and traded slightly above $2 in the early sessions, valuing the company at $22 million. Market watchers are bullish on the stock’s growth prospects over the next twelve months and expect the value to more than double.
Trxade is a rapidly growing company that is well-positioned to tap into the positive changes in the prescription drug market. The company stands to benefit from the widespread adoption of technology and the growing need to digitalize healthcare services, thanks to its innovative products. The company’s quick response to the pandemic, by offering the required monitoring tools or telemedicine services, underscores its relevance in times of emergency.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
These fast-food stocks can strengthen your portfolio this year. Here’s why
For American restaurant chains, the early months of the pandemic were a challenging period. But soon things changed for the better as people started ordering their favorite food items online
What to expect when McCormick & Company (MKC) reports Q1 results next week
Shares of McCormick & Company, Incorporated (NYSE: MKC) were up over 2% on Friday. The stock has dropped 12% year-to-date. The condiments manufacturer is scheduled to report its first quarter 2023
KB Home (KBH) Earnings: 1Q23 Key Numbers
KB Home (NYSE: KBH) reported total revenues of $1.38 billion for the first quarter of 2023 which was relatively flat compared to the same period last year. Net income of